Compare Charles River Laboratories Intl. Inc (CRL) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while YieldMax Universe Fund of Option Income ETFs trades at $7.62 (market cap $364M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 39.1× YieldMax Universe Fund of Option Income ETFs's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and YieldMax Universe Fund of Option Income ETFs for 56 Days on average.
| CRL | YMAX | |
|---|---|---|
Market Cap | $14.23B | $364M |
Volume | 1,176,885 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $310.77 | $12.98 |
52-Week Low | $149.93 | $7.27 |
Typical Hold Time | 33 Days | 56 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
YMAX trades at $7.61, up 1.06% with a bearish technical outlook. The ETF shows persistent NAV erosion despite weekly distributions, with the share price declining 22.7% year-to-date. Recent portfolio adjustments and a 40%+ annualized yield highlight structural concerns about distribution sustainability. Technical indicators show bearish moving averages and neutral oscillators with support at $7 and resistance at $8.
The outlook remains cautious due to ongoing principal erosion and high fees. While the high yield attracts income investors, the fund-of-funds structure adds layered costs. Analyst sentiment is neutral to bearish, with concerns about long-term viability outweighing short-term income benefits. Key risks include distribution policy sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
